NRG1-Fusionen treten in ~0,5 % des Pankreas-Dynamus-Adenokarzinoms (PDAC) auf — ein seltenes, aber...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BMA-NRG1-FUSION-PDAC |
|---|---|
| Art | Therapeutische Relevanz |
| Status | reviewed 2026-05-03 | pending_clinical_signoff | actionability review required |
| Erkrankungen | DIS-PDAC |
| Quellen | SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Fakten zur Handlungsfähigkeit
| Biomarker | BIO-NRG1-FUSION |
|---|---|
| Variante | NRG1-Genfusion — jeder Fusionspartner (RBPMS-NRG1, SLC3A2-NRG1-PMEPA1-NRG1), der am häufigsten in PDAC vorkommt; nachgewiesen durch RNA-Seq) |
| Erkrankung | DIS-PDAC |
| ESCAT-Stufe | IIA |
| Empfohlene Kombinationen | zenocutuzumab 750 mg IV q2w monotherapy (post-gemcitabine-based or post-FOLFIRINOX; CRESTONE regimen) |
| Zusammenfassung der Beweise | NRG1 fusions occur in ~0.5% of pancreatic ductal adenocarcinoma (PDAC) — a rare but actionable subset. Zenocutuzumab (MCLA-128), anti-HER2/HER3 bispecific antibody, FDA accelerated approval (Nov 2024) for NRG1 fusion-positive locally advanced or metastatic NSCLC and pancreatic adenocarcinoma after prior systemic therapy. CRESTONE trial (Schram et al. JCO 2024): NRG1-fusion PDAC cohort — ORR 40%, mDOR 9.1 mo, mPFS 8.7 mo — particularly notable given the ~3 mo mPFS typically seen with 2L-3L chemotherapy in PDAC. NRG1-fusion PDAC is likely KRAS-wild-type in >90% of cases (oncogenic KRAS and NRG1 fusion may be functionally redundant). RNA sequencing required — DNA NGS panels miss most NRG1 fusions. |
Anmerkungen
ESCAT IIA (accelerated approval based on ORR; confirmatory data pending). NRG1-fusion PDAC is enriched in KRAS-wild-type tumors (testing KRAS early identifies a subpopulation that warrants comprehensive RNA-seq). ORR of 40% in CRESTONE PDAC cohort is particularly impactful given the absence of other effective targeted therapies in 2L-3L PDAC. Testing strategy: if KRAS-wild-type PDAC identified, proceed to RNA-based comprehensive genomic profiling to detect NRG1 (and other rare fusions: NTRK, ALK, RET, FGFR). Zenocutuzumab is generally well tolerated: infusion reactions (premedication required), fatigue, nausea; no grade 3-4 cardiotoxicity seen in CRESTONE.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.